Kite Pharma (KITE) Earns News Sentiment Rating of 0.15
News coverage about Kite Pharma (NASDAQ:KITE) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kite Pharma earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.8451457892985 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Bolder Novo Nordisk Emerges With $3.1 Billion Ablynx Pursuit – Bloomberg (bloomberg.com)
- UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer – GlobeNewswire (press release) (globenewswire.com)
- Why 2017 Was a Year to Remember for Gilead Sciences, Inc. – Motley Fool (fool.com)
- 2018 Biotech preview: The biotech industry aims to find solutions for the worst maladies – San Francisco Business Times (bizjournals.com)
Kite Pharma (KITE) remained flat at $$179.79 on Tuesday. The stock has a market capitalization of $10,280.00 and a price-to-earnings ratio of -26.06. Kite Pharma has a 12 month low of $39.82 and a 12 month high of $179.95.
About Kite Pharma
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Stock Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related stocks with our FREE daily email newsletter.